Clinical trial
A Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting…
NCT00216528 · Janssen Korea, Ltd., Korea, Industry · Completed
Key facts
| NCT number | NCT00216528 |
|---|---|
| Title | A Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone Microspheres |
| Official title | A Prospective, Open-Label Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone Microspheres (Risperdal Consta) |
| Lead sponsor | Janssen Korea, Ltd., Korea, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | risperidone |
| Enrollment | 527 |
| Start date | Jul 1, 2005 |
| Completion | Apr 1, 2007 |
| First posted | Sep 22, 2005 |
| Last update posted | Apr 27, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: